Added micronisation at Catalent
Catalent has completed a $10 million expansion in large-scale isolator units at its sites in Malvern, Pennsylvania, and Dartford, UK. These provide advanced containment capabilities for the micronisation of highly potent drug compounds.
Both sites feature hard-wall isolator systems allowing clinical- to commercial-scale jet milling operations to be carried out at OEL down to 0.5 ug/m3. Micronisers purged with nitrogen can be installed within these to eliminate the risk of dust explosion for compounds with low minimum ignition values. They also offer continuous milling to eliminate the need to stop and change out material and clean-in-place automated washing systems.
RELATED ARTICLES
Swiss CDMO Siegfried has inaugurated its new global R&D centre for drug substances at its site in Evionnaz.
Peptides CDMO AmbioPharm, has broken ground on a 650 m2, $28 million expansion project at its Shanghai manufacturing site. This is due to be complete in 2H 2025 and will produce over 8 tonnes/year of crude peptide.
Three CDMOs have separately announced expansions in their antibody-drug conjugate (ADC) manufacturing capabilities and capacity on opposite sides of the Atlantic.
Biosynth, which supplies critical raw materials and services for diagnostics, vaccines and pharmaceuticals, has officially opened its Biosynth Biological Technology site at Lifebay, a technology park in Suzhou, China.
At its latest Capital Markets Day, Merck KGaA said that it is “in a strong strategic position” to profit from medium-term growth opportunities in all three of its business sectors after a transitional year in 2023.
At CPHI in Milan in October, eight Indian CDMOs announced that they have formed a trade group to raise the profile of India’s drug services sector and make it a destination of choice.
